| MiCBT Research – Selected Studies

Combined identification of lncRNA NONHSAG004550 and NONHSAT125420 as a potential diagnostic biomarker of perinatal depression

Li Wang1, Ming Zhang2, Haiyan Zhu1, Liying Sun1, Bin Yu3, Xuelian Cui1

1Department of Healthcare, Changzhou Maternity and Child Health Care Hospital affiliated with Nanjing Medical University, Changzhou, China
2Department of Clinical Laboratory, Changzhou Maternity and Child Health Care Hospital affiliated with Nanjing Medical University, Changzhou, China
3Department of Genetic Laboratory, Changzhou Maternity and Child Health Care Hospital affiliated with Nanjing Medical University, Changzhou, China


Background: Perinatal depression (PD) is one of the most common complications of pregnancy, and timely diagnosis and treatment are still challenging in China due to the scarcity of psychiatrists. This study aimed to investigate whether long noncoding RNAs (lncRNAs) are potential diagnostic biomarkers of PD.

Methods: Using RT-PCR, six downregulated major depressive disorder (MDD)-associated lncRNAs (NONSUSG010267, NONHSAT140386, NONHSAG004550, NONHSAT125420, NONHSAG013606, and NONMMUG014361) were assessed in 39 pregnant women with PD (PD group), 20 PD patients undergoing mindfulness-integrated cognitive behavior therapy (MiCBT) (treatment group (TG)), and 51 normal pregnant women (normal control (NC) group) to identify significantly differentially expressed lncRNAs during the second trimester and at 42 days postpartum.

Results: Compared with the NC group, the six lncRNAs were significantly downregulated in the PD group during the second trimester and at 42 days postpartum (p<0.01~0.001). Expression of NONHSAG004550 and NONHSAT125420 was significantly upregulated after MiCBT therapy in TG (p<0.01~0.001), and no significant differences were observed between TG and the NC group at 42 days postpartum (p>0.05). NONHSAG004550 and NONHSAT125420 were significantly differentially expressed in the PD group, and this expression was altered according to the amelioration of depressive symptoms. Receiver operating characteristic (ROC) curve analysis revealed that the two lncRNAs combined had a good value in predicting PD, with an area under the curve (AUC) of 0.764 (95% confidence interval (CI): 0.639–0.888).

Conclusion: The combination of lncRNAs NONHSAG004550 and NONHSAT125420 is a novel potential diagnostic biomarker of PD.

Read the full article here:
Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.

Effectiveness of Mindfulness-integrated Cognitive Behavioural Therapy (MiCBT) on body image and emotional regulation in mastectomy patients: a randomized clinical trial

July 10, 2023

Efficacy of mindfulness and goal setting interventions for increasing resilience and reducing smoking in lower socioeconomic groups: randomised controlled trial protocol

February 6, 2023

Confirmation and Validation of the Equanimity Scale-16 (ES-16)

December 4, 2022

La MiCBT une nouvelle approche des interventions basées sur la pleine conscience: différences et similarités de 3 thérapies

November 9, 2022

(ES- ویژگیهای روانسنجی نسخه فارسی مقیاس تعادل ذهنی ( 16
Psychometric Properties of the Persian Version of Equanimity Scale 16 (ES-16)

November 7, 2022

The Equanimity Scale-16

October 31, 2022

Group Mindfulness-Integrated Cognitive Behavior Therapy (MiCBT) Reduces Depression and Anxiety and Improves Flourishing in a Transdiagnostic Primary Care Sample Compared to Treatment-as-Usual: A Randomized Controlled Trial

June 10, 2022

Validation and Factor Structure of the Mindfulness‑Based Self Efficacy Scale‑Revised

February 7, 2022

Managing type 2 diabetes and depression with Mindfulness-integrated Cognitive Behavior Therapy (MiCBT)

February 2, 2022

The Effectiveness of Mindfulness-integrated Cognitive Behavioral Therapy (MiCBT), Meta-Cognitive Therapy (MCT), Acceptance and Commitment Therapy (ACT), and Cognitive Behavioral Therapy (CBT) on Obsessive-compulsive disorder (OCD)

October 15, 2021
Scroll to Top